Anticipated Clinical Milestones: DA-1726 in Obesity: Top-line data from the single ascending dose Part 1 is expected in the third quarter of 2024. Initiation of the multiple ascending dose study Part 2 is expected in the third quarter of 2024 and the top-line data expected in the first quarter of 2025. DA-1241 in MASH: Full enrollment of the two-part Phase 2a clinical trial of DA-1241 in MASH is expected in the third quarter of 2024. Top-line results are expected to be available in the fourth quarter of 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRBO:
- NeuroBo Pharmaceuticals management to meet with Maxim Group
- NeuroBo Pharmaceuticals doses first patient in Phase 1 DA-1726 trial
- NeuroBo Pharmaceuticals files $150M mixed securities shelf
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
- NeuroBo Pharmaceuticals cleared to continue Phase 2a trial of DA-1241